213 68

Full metadata record

DC FieldValueLanguage
dc.contributor.author윤채옥-
dc.date.accessioned2022-12-09T06:47:38Z-
dc.date.available2022-12-09T06:47:38Z-
dc.date.issued2022-02-
dc.identifier.citationFRONTIERS IN IMMUNOLOGY, v. 13, article no. 826876, Page. 1-22en_US
dc.identifier.issn1664-3224;1664-3224en_US
dc.identifier.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2022.826876/fullen_US
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/178118-
dc.description.abstractImmunotherapy holds enormous promise to create a new outlook of cancer therapy by eliminating tumors via activation of the immune system. In immunotherapy, polymeric systems play a significant role in improving antitumor efficacy and safety profile. Polymeric systems possess many favorable properties, including magnificent biocompatibility and biodegradability, structural and component diversity, easy and controllable fabrication, and high loading capacity for immune-related substances. These properties allow polymeric systems to perform multiple functions in immunotherapy, such as immune stimulants, modifying and activating T cells, delivery system for immune cargos, or as an artificial antigen-presenting cell. Among diverse immunotherapies, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T cell, and oncolytic virus recently have been dramatically investigated for their remarkable success in clinical trials. In this report, we review the monotherapy status of immune checkpoint inhibitors, CAR-T cell, and oncolytic virus, and their current combination strategies with diverse polymeric systems.en_US
dc.description.sponsorshipAcknowledgments This research was supported by grants from the National Research Foundation of Korea (2016M3A9B5942352 and 2021R1A2C301016611, C-OY).en_US
dc.languageenen_US
dc.publisherFRONTIERS MEDIA SAen_US
dc.subjectimmune checkpoint inhibitoren_US
dc.subjectimmunotherapyen_US
dc.subjectpolymeric systemen_US
dc.subjectoncolytic adenovirusen_US
dc.subjectCAR-T cellen_US
dc.titlePolymeric Systems for Cancer Immunotherapy: A Reviewen_US
dc.typeArticleen_US
dc.relation.volume13-
dc.identifier.doi10.3389/fimmu.2022.826876en_US
dc.relation.page1-22-
dc.relation.journalFRONTIERS IN IMMUNOLOGY-
dc.contributor.googleauthorLe, Thai Minh Duy-
dc.contributor.googleauthorYoon, A-Rum-
dc.contributor.googleauthorThambi, Thavasyappan-
dc.contributor.googleauthorYun, Chae-Ok-
dc.sector.campusS-
dc.sector.daehak공과대학-
dc.sector.department생명공학과-
dc.identifier.pidchaeok-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE